Literature DB >> 5000339

Clinical experience with determination of fibrinogen degradation products.

U Hedner, M Nilsson.   

Abstract

Mesh:

Substances:

Year:  1971        PMID: 5000339     DOI: 10.1111/j.0954-6820.1971.tb04407.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


× No keyword cloud information.
  8 in total

1.  Enhanced antiplasmin activity in acute renal failure.

Authors:  A Kanfer; A Vandewalle; M Beaufils; F Delarue; J D Sraer
Journal:  Br Med J       Date:  1975-10-25

2.  Boerhaave syndrome: report of a case treated non-operatively.

Authors:  A J Larrieu; R Kieffer
Journal:  Ann Surg       Date:  1975-04       Impact factor: 12.969

3.  Fibrinolytic inhibitors in human seminal plasma.

Authors:  P Liedholm; B Astedt
Journal:  Experientia       Date:  1974-10-15

4.  Fibrin degradation products in hypoxic full-term neonates.

Authors:  H Ekelund; O Finnstrom
Journal:  Br Med J       Date:  1972-01-29

5.  Development and treatment of post-traumatic pulmonary platelet trapping.

Authors:  R M Peer; S I Schwartz
Journal:  Ann Surg       Date:  1975-04       Impact factor: 12.969

6.  Measurement of fibrinogen-fibrin-related antigen in serum as aid to diagnosis of deep vein thrombosis in outpatients.

Authors:  D A Tibbutt; C N Chesterman; M J Allington; E W Williams; T Faulkner
Journal:  Br Med J       Date:  1975-02-15

7.  Blood coagulation studies in patients with advanced carcinoma of the prostate treated with 2,6-cis-diphenylhexamethylcyclotetrasiloxane or estramustine-17-phosphate.

Authors:  M Blombäck; F Edsmyr; C Kockum; C Paul
Journal:  Urol Res       Date:  1978

8.  Levels of fibrinogen/fibrin degradation fragment E and related substances in sera and effusions of patients with malignant disease.

Authors:  Z Gilead; R Zahavi; A Hatzubai; G Brufman; S Biran; D Sulitzeanu
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.